Armine Galstyan
Armine Galstyan has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Diana A. Ivanova
The Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health ; The Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
1 shared publication Diana Ivanova
Moscow Research and Clinical Center for TB Control, Moscow, Russian Federation
1 shared publicationE. Yu. Romanova
The Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
1 shared publicationLudmila Slogodskay
Moscow Research and Clinical Center for TB Control, Moscow, Russian Federation
1 shared publicationMichail Sinitsyn
Moscow Research and Clinical Center for TB Control, Moscow, Russian Federation
1 shared publication- O. V. Rodina
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы
1 shared publication
Latest Publications
- Open Access
- 23 January 2026
- Published by In-Trend in Tuberculosis and socially significant diseases
- Vol. 13 (3) , 25-36
Antiviral therapy for hepatitis C in patients with tuberculosis
The aim. The study was to evaluate the effectiveness and safety of co-administration of antituberculosis and antiviral therapy (AVT) in patients with coinfection of chronic viral hepatitis C and pulmonary tuberculosis. Materials and methods. The observational study included 52 patients with active tuberculosis (63.5% drug-resistant cases) and chronic viral hepatitis C; 11 of them received a course of antiviral therapy (pan-genotypic regimens), 8 patients – simultaneously with anti-tuberculosis treatment (ATT, regimens without rifampicin), another 3 – before the start of tuberculosis treatment. Results. All 8 patients (100%) who received simultaneous AVT and ATT demonstrated a virological response; 7 days after the start of AVT, a complete normalization of transaminase levels was observed, which made it possible to prescribe an adequate ATT regimen and achieve successful treatment of tuberculosis. Two patients experienced mild adverse reactions, including transient eosinophilia, associated with the use of anti-tuberculosis drugs. After AVT, liver enzyme levels remained normal until completion of anti-tuberculosis treatment; in group without AVT (n = 41), the incidence of drug-induced liver injury was 61.0% (p < 0.001). Conclusion. Co-administration of anti-tuberculosis and antiviral therapy in tuberculosis patients with chronic hepatitis C is safe and effective. Pangenotypic AVT regimens are optimal. It is better to start including anti-tuberculosis drugs from the second week of antiviral treatment.
- 23 January 2026
- Published by In-Trend in Tuberculosis and socially significant diseases
- Vol. 13 (3) , 25-36
Open AccessAntiviral therapy for hepatitis C in patients with tuberculosis
The aim. The study was to evaluate the effectiveness and safety of co-administration of antituberculosis and antiviral therapy (AVT) in patients with coinfection of chronic viral hepatitis C and pulmonary tuberculosis. Materials and methods. The observational study included 52 patients with active tuberculosis (63.5% drug-resistant cases) and chronic viral hepatitis C; 11 of them received a course of antiviral therapy (pan-genotypic regimens), 8 patients – simultaneously with anti-tuberculosis treatment (ATT, regimens without rifampicin), another 3 – before the start of tuberculosis treatment. Results. All 8 patients (100%) who received simultaneous AVT and ATT demonstrated a virological response; 7 days after the start of AVT, a complete normalization of transaminase levels was observed, which made it possible to prescribe an adequate ATT regimen and achieve successful treatment of tuberculosis. Two patients experienced mild adverse reactions, including transient eosinophilia, associated with the use of anti-tuberculosis drugs. After AVT, liver enzyme levels remained normal until completion of anti-tuberculosis treatment; in group without AVT (n = 41), the incidence of drug-induced liver injury was 61.0% (p < 0.001). Conclusion. Co-administration of anti-tuberculosis and antiviral therapy in tuberculosis patients with chronic hepatitis C is safe and effective. Pangenotypic AVT regimens are optimal. It is better to start including anti-tuberculosis drugs from the second week of antiviral treatment.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA2990
Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients
Background: The use of Bedaquiline-containing regimens improves outcomes of treatment, but the safety of bedaquiline (Bdq) in HIV patients is not enough studied. The aim was to analyze the frequency and severity of adverse drug reactions (ADRs) during bedaquiline-containing anti-tuberculosis therapy (ATT) in HIV/TB co-infected patients. Methods: 57 HIV co-infected patients with drug-resistant pulmonary TB (71.9% male, med 36 y.o., MDR in 21, XDR in 34) were monitored for ADRs during the first 6 month of ATT including Bdq (regimens were formed according to WHO recommendations). 56 were culture-positive; 13 had extrapulmonary TB; 56 (98.2%) – HIV infection of grade 4, with baseline СD4+ level of 11-1745 (med 171); all received antiretroviral therapy (either first- or second-line regimens without considering Bdq use). ADRs having DMID Grade 3-4 were recorded as serious. Results: only 8 patients (14.0%, 95%CI 7.0-25.6%) experienced at least one ADR, to a total of 10 events: 5 – gastrointestinal disorders, 1 – clinically significant sinus bradycardia (45-50 heart beats/min), 1 – QTcF prolongation (512 ms) with episodes of non-sustained “torsades de pointes” (the patient received Bdq, moxifloxacin and azithromycin simultaneously), 1 – deafness, 1 – hepatitis and 1 – tendinopathy. SADR were registered in 3 pts (5.3%, 95%CI 1.2-14.9%). Bdq was discontinued due to ADR in 4 pts (7.0%), 2 with QTcF prolongation/bradycardia and 2 with gastrointestinal disorders. Conclusion: bedaquiline-containing regimens appear to show reassuring safety profile with low frequency of serious adverse reactions.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA2990
Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients
Background: The use of Bedaquiline-containing regimens improves outcomes of treatment, but the safety of bedaquiline (Bdq) in HIV patients is not enough studied. The aim was to analyze the frequency and severity of adverse drug reactions (ADRs) during bedaquiline-containing anti-tuberculosis therapy (ATT) in HIV/TB co-infected patients. Methods: 57 HIV co-infected patients with drug-resistant pulmonary TB (71.9% male, med 36 y.o., MDR in 21, XDR in 34) were monitored for ADRs during the first 6 month of ATT including Bdq (regimens were formed according to WHO recommendations). 56 were culture-positive; 13 had extrapulmonary TB; 56 (98.2%) – HIV infection of grade 4, with baseline СD4+ level of 11-1745 (med 171); all received antiretroviral therapy (either first- or second-line regimens without considering Bdq use). ADRs having DMID Grade 3-4 were recorded as serious. Results: only 8 patients (14.0%, 95%CI 7.0-25.6%) experienced at least one ADR, to a total of 10 events: 5 – gastrointestinal disorders, 1 – clinically significant sinus bradycardia (45-50 heart beats/min), 1 – QTcF prolongation (512 ms) with episodes of non-sustained “torsades de pointes” (the patient received Bdq, moxifloxacin and azithromycin simultaneously), 1 – deafness, 1 – hepatitis and 1 – tendinopathy. SADR were registered in 3 pts (5.3%, 95%CI 1.2-14.9%). Bdq was discontinued due to ADR in 4 pts (7.0%), 2 with QTcF prolongation/bradycardia and 2 with gastrointestinal disorders. Conclusion: bedaquiline-containing regimens appear to show reassuring safety profile with low frequency of serious adverse reactions.